← Product Code [JJX](/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/JJX) · K961206 # OPUS T3 CONTROLS (K961206) _Behring Diagnostics, Inc. · JJX · Apr 23, 1996 · Clinical Chemistry · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/JJX/K961206 ## Device Facts - **Applicant:** Behring Diagnostics, Inc. - **Product Code:** [JJX](/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/JJX.md) - **Decision Date:** Apr 23, 1996 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 862.1660 - **Device Class:** Class 1 - **Review Panel:** Clinical Chemistry ## Indications for Use The OPUS T3 Controls are intended for use as quality control material to monitor the precision and accuracy of the OPUS T3 assay. ## Device Story OPUS T3 Controls consist of liquid, tri-level human serum-based matrix containing known T3 levels, anti-microbial agents, and sodium azide. Used exclusively with OPUS Immunoassay System to monitor assay precision and accuracy. Laboratory personnel perform testing; results compared against lot-specific values to validate assay performance. Benefits include ensuring reliable diagnostic results for T3 testing. ## Clinical Evidence Bench testing only. Precision evaluated on OPUS Immunoassay System. Intra-assay precision (n=20) yielded %CVs of 7.1% to 12.8%. Inter-assay precision (n=20, duplicate determinations twice daily for five days) yielded %CVs of 13.1% to 17.9%. ## Technological Characteristics Liquid tri-level human serum-based matrix; contains T3, anti-microbial agents, and sodium azide. Designed for use with OPUS Immunoassay System. No specific material standards or software algorithms described. ## Regulatory Identification A quality control material (assayed and unassayed) for clinical chemistry is a device intended for medical purposes for use in a test system to estimate test precision and to detect systematic analytical deviations that may arise from reagent or analytical instrument variation. A quality control material (assayed and unassayed) may be used for proficiency testing in interlaboratory surveys. This generic type of device includes controls (assayed and unassayed) for blood gases, electrolytes, enzymes, multianalytes (all kinds), single (specified) analytes, or urinalysis controls. ## Predicate Devices - OPUS hCG Controls ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0} K961206 attachment 1 APR 23 1996 $$ \angle -961206 $$ # 510(k) Summary of Safety and Effectiveness for OPUS T3 Controls 1. Manufacturer Name, Address, phone number, contact name and date of preparation: Manufacturer: Behring Diagnostics Inc., 151 University Avenue Westwood, MA 02090 617-320-3153 Contact name: Nancy M Johansen date of preparation: March 26, 1996 2. Device Name/Classification: Quality Control Material (assayed)/Class I (862.1660) 3. Identification of the legally marketed device to which the submitter claims equivalence. OPUS hCG Controls 2. Proposed Device Description: The OPUS T3 Controls are liquid controls containing known levels of T3 in processed human serum with anti-microbial agents and sodium azide as preservatives. The control is provided at three levels (low, mid and high). The OPUS T3 control is only for use with the OPUS T3 assay and has not been evaluated for use with other assays. 3. Proposed Device Intended Use: The OPUS T3 Controls are intended for use as quality control material to monitor the precision and accuracy of the OPUS T3 assay. {1} attachment ## 4. Medical device to which equivalence is claimed and comparison information: The OPUS T3 Controls are substantially equivalent in intended use to the OPUS hCG Controls. Both products are *in vitro* diagnostic reagents intended for use as a quality control material to monitor specific laboratory procedures. The OPUS T3 Controls like the OPUS hCG Controls are liquid tri-level human serum based matrix controls. Both controls are provided with lot specific values and are for use with the OPUS assays only. The OPUS T3 Controls differ from the OPUS hCG Controls in that the OPUS T3 Controls are for use with the OPUS T3 assay and contain known levels of T3 while the OPUS hCG Controls are for use with the OPUS hCG assay and contain known levels of hCG. ## 5. Proposed Device Performance Characteristics: Precision of the OPUS T3 Controls was evaluated on an OPUS Immunoassay System. intra assay precision was evaluated by running an n=20 with each level of the OPUS controls. %CV's ranged from 7.1 to 12.8 %. The inter assay precision was evaluated by running duplicate determinations for each level of control twice per day (AM and PM) for five days to total an n=20. %CV's ranged from 13.1% to 17.9%. --- **Source:** [https://fda.innolitics.com/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/JJX/K961206](https://fda.innolitics.com/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/JJX/K961206) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com